公开(公告)号：US20100317868A1

公开(公告)日：2010-12-16

申请号：US12517980

申请日：2007-11-20

Applicant: Nam Du Kim ,  Wooseob Shin ,  Jaehyuk Jung ,  Dong Jun Kim ,  Gi Jeong Kim ,  Young Ho Moon ,  Young-Kil Chang ,  Gwan Sun Lee ,  Tae Jin Choi

Inventor： Nam Du Kim ,  Wooseob Shin ,  Jaehyuk Jung ,  Dong Jun Kim ,  Gi Jeong Kim ,  Young Ho Moon ,  Young-Kil Chang ,  Gwan Sun Lee ,  Tae Jin Choi

IPC: C07D263/06 ,  C07D305/14

CPC classification number: C07D305/14 ,  Y02P20/55

Abstract: The present invention relates to a novel method of preparing a taxane derivative having an anti-tumor and anti-leukemia activity, and intermediates used therein.

Abstract translation: 本发明涉及一种制备具有抗肿瘤和抗白血病活性的紫杉烷衍生物的新方法及其中使用的中间体。

公开(公告)号：US20100261248A1

公开(公告)日：2010-10-14

申请号：US12759801

申请日：2010-04-14

Applicant: Young Min KIM ,  Dae Hae Song ,  Sung Youb Jung ,  Chang Hwan Kim ,  In Young Choi ,  Se Chang Kwon ,  Gwan Sun Lee

Inventor： Young Min KIM ,  Dae Hae Song ,  Sung Youb Jung ,  Chang Hwan Kim ,  In Young Choi ,  Se Chang Kwon ,  Gwan Sun Lee

IPC: C07K16/00 ,  C07K14/76 ,  C07K14/775 ,  C07K14/805 ,  C07K14/555 ,  C07K14/54 ,  C07K14/56 ,  C12N9/00 ,  C07K14/755

CPC classification number: C07K19/00 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  A61K2039/505 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/30

Abstract: Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

Abstract translation: 公开了免疫球蛋白Fc片段的新用途，更具体地，涉及包含免疫球蛋白Fc片段作为载体的药物组合物。 包含作为载体的免疫球蛋白Fc片段的药物组合物显着延长了药物的血清半衰期，同时保持药物的体内活性在相对高的水平。 此外，当药物是多肽药物时，与免疫球蛋白Fc片段和靶蛋白质的融合蛋白相比，药物组合物诱导免疫应答的风险较小，因此可用于开发各种多肽药物的长效制剂。

公开(公告)号：US20100190983A1

公开(公告)日：2010-07-29

申请号：US12669002

申请日：2008-08-04

Applicant: Young Ho Moon ,  Moon Sub Lee ,  Jae Ho Yoo ,  Ji Sook Kim ,  Han Kyong Kim ,  Chang Ju Choi ,  Young Kil Chang ,  Gwan Sun Lee

Inventor： Young Ho Moon ,  Moon Sub Lee ,  Jae Ho Yoo ,  Ji Sook Kim ,  Han Kyong Kim ,  Chang Ju Choi ,  Young Kil Chang ,  Gwan Sun Lee

IPC: C07D239/38 ,  C07D403/06

CPC classification number: C07D403/06

Abstract: Optically pure voriconazole can be prepared in a high yield by a) subjecting 1-(2,4-difluorophenyl)-2(1H-1,2,4-triazol-1-yl)ethanone to Reformatsky-type coupling reaction with a substituted thiopyrimidine derivative to obtain a desired (2R,3S)/(2S,3R)-enantiomeric pair; b) removing the thiol derivative from the enantiomer to obtain racemic voriconazole; and c) isolating the racemic voriconazole by way of optical resolution using an optically active acid.

Abstract translation: 可以通过以下方法制备光学纯的伏立康唑：a）使1-（2,4-二氟苯基）-2（1H-1,2,4-三唑-1-基）乙酮与取代基进行重新加成型偶联反应 硫代嘧啶衍生物，得到所需的（2R，3S）/（2S，3R） - 对映异构体对; b）从对映异构体中除去硫醇衍生物，得到外消旋的伏立康唑; 和c）使用光学活性酸通过光学拆分分离外消旋的伏立康唑。

公开(公告)号：US07736653B2

公开(公告)日：2010-06-15

申请号：US10535231

申请日：2004-11-13

Applicant: Young Min Kim ,  Dac Hae Song ,  Sung Youb Jung ,  Chang Hwan Kim ,  In Young Choi ,  Se Chang Kwon ,  Gwan Sun Lee

Inventor： Young Min Kim ,  Dac Hae Song ,  Sung Youb Jung ,  Chang Hwan Kim ,  In Young Choi ,  Se Chang Kwon ,  Gwan Sun Lee

IPC: A61K39/395 ,  A61K38/16

CPC classification number: A61K47/68 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/61 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30

Abstract: Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

Abstract translation: 公开了免疫球蛋白Fc片段的新用途，更具体地，涉及包含免疫球蛋白Fc片段作为载体的药物组合物。 包含作为载体的免疫球蛋白Fc片段的药物组合物显着延长了药物的血清半衰期，同时保持药物的体内活性在相对高的水平。 此外，当药物是多肽药物时，与免疫球蛋白Fc片段和靶蛋白质的融合蛋白相比，药物组合物诱导免疫应答的风险较小，因此可用于开发各种多肽药物的长效制剂。

公开(公告)号：US07718399B2

公开(公告)日：2010-05-18

申请号：US10576068

申请日：2004-10-14

Applicant: Sung Youb Jung ,  Jin Sun Kim ,  Se Chang Kwon ,  Gwan Sun Lee

Inventor： Sung Youb Jung ,  Jin Sun Kim ,  Se Chang Kwon ,  Gwan Sun Lee

IPC: C12P21/06 ,  C07K14/00

CPC classification number: C12P21/02 ,  C07K16/00 ,  C07K16/241 ,  C07K2317/55 ,  C07K2319/00 ,  C07K2319/02 ,  C12N15/70

Abstract: A recombinant expression vector capable of expressing and secreting an antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative or E. coli outer membrane protein A (Omp A) signal sequence in the form of a soluble heterozygote protein is used to mass-produce the antibody fragment by culturing a microorganism transformed with the expression vector in a medium and collecting the antibody fragment secreted from the transformed microorganism into the medium.

Abstract translation: 能够表达和分泌与大肠杆菌热稳定性肠毒素信号序列衍生物或可溶性杂合子蛋白质形式的大肠杆菌外膜蛋白A（Omp A）信号序列融合的抗体片段的重组表达载体用于批量生产 通过在培养基中培养用表达载体转化的微生物并将从转化的微生物分泌的抗体片段收集到培养基中的抗体片段。

公开(公告)号：US20100120089A1

公开(公告)日：2010-05-13

申请号：US12444567

申请日：2007-10-16

Applicant: In Young Choi ,  Chang Hwan Kim ,  Hyun Ji Lee ,  Seong Hee Park ,  Se Chang Kwon ,  Gwan Sun Lee

Inventor： In Young Choi ,  Chang Hwan Kim ,  Hyun Ji Lee ,  Seong Hee Park ,  Se Chang Kwon ,  Gwan Sun Lee

IPC: C12P21/00 ,  C12N15/74 ,  C12N5/10

CPC classification number: C12N9/003 ,  C12N15/85 ,  C12N2510/00

Abstract: Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.

Abstract translation: 本文公开了包含二氢叶酸还原酶（DHFR）启动子的诱导型高表达盒，从其中部分或全部除去富含GC的重复序列，所述盒能够更有效地改善基因扩增系统。 还公开了包含可诱导表达盒和任选的编码目标重组蛋白的基因，用表达载体转化的动物细胞系的表达载体，以及通过培养转化体大量生产和纯化重组蛋白的方法。 本发明能够缩短使用低浓度的DHFR抑制剂以高水平建立产生重组蛋白质的细胞系所需的时间，从而允许更有效地产生重组蛋白质。

公开(公告)号：US20100099897A1

公开(公告)日：2010-04-22

申请号：US12532887

申请日：2008-04-10

Applicant: Namdu Kim ,  Woo Seob Shin ,  Jaehyuk Jung ,  Gi Jeong Kim ,  Seung Hwan Cho ,  Eun Jung Lim ,  Youngho Moon ,  Young-Kil Chang ,  Gwan Sun Lee

Inventor： Namdu Kim ,  Woo Seob Shin ,  Jaehyuk Jung ,  Gi Jeong Kim ,  Seung Hwan Cho ,  Eun Jung Lim ,  Youngho Moon ,  Young-Kil Chang ,  Gwan Sun Lee

IPC: C07D305/14

CPC classification number: C07D305/14

Abstract: The present invention provides a stable anhydrous crystalline docetaxel which has anti-tumor and anti-leukemia activity, and method for the preparation thereof.

Abstract translation: 本发明提供了具有抗肿瘤和抗白血病活性的稳定的无水结晶多西紫杉醇及其制备方法。

公开(公告)号：US20090209576A1

公开(公告)日：2009-08-20

申请号：US12293357

申请日：2007-03-15

Applicant: Won Jeoung Kim ,  Han Kyong Kim ,  Kwee Hyun Suh ,  Gwan Sun Lee

Inventor： Won Jeoung Kim ,  Han Kyong Kim ,  Kwee Hyun Suh ,  Gwan Sun Lee

IPC: A61K31/4365 ,  C07D495/04 ,  A61P7/00

CPC classification number: A61K31/47

Abstract: A pharmaceutical composition of the present invention which comprises clopidogrel camphorsulfonate of formula (I) or its polymorphic forms as an active ingredient is useful for treating or preventing a platelet aggregation-associated disease.

Abstract translation: 包含式（I）的氯吡格雷樟脑磺酸盐或其多晶型物质作为活性成分的本发明的药物组合物可用于治疗或预防血小板聚集相关疾病。

公开(公告)号：US07576219B2

公开(公告)日：2009-08-18

申请号：US11374034

申请日：2006-03-14

Applicant: Tae Hee Ha ,  Hee Sook Oh ,  Won Jeoung Kim ,  Chang Hee Park ,  Eun Young Kim ,  Young Hoon Kim ,  Kwee Hyun Suh ,  Gwan Sun Lee

Inventor： Tae Hee Ha ,  Hee Sook Oh ,  Won Jeoung Kim ,  Chang Hee Park ,  Eun Young Kim ,  Young Hoon Kim ,  Kwee Hyun Suh ,  Gwan Sun Lee

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Abstract translation: 本发明提供了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑水合锶，其具有高光学纯度，耐受性，溶解性和不吸湿性，其制备方法和含有该组合物的药物组合物。

公开(公告)号：US20090053246A1

公开(公告)日：2009-02-26

申请号：US11910962

申请日：2005-04-28

Applicant: Young Min Kim ,  Sung Min Bae ,  Dae Jin Kim ,  Dae Hae Song ,  Chang Ki Lim ,  Se Chang Kwon ,  Gwan Sun Lee

Inventor： Young Min Kim ,  Sung Min Bae ,  Dae Jin Kim ,  Dae Hae Song ,  Chang Ki Lim ,  Se Chang Kwon ,  Gwan Sun Lee

IPC: C07K19/00 ,  C07K16/00 ,  A61K39/44

CPC classification number: A61K47/6835 ,  A61K47/6811 ,  A61K47/6813 ,  C07K2317/52 ,  C07K2319/30

Abstract: Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses.

Abstract translation: 公开了由非肽聚合物修饰的Fc片段，包含由作为载体的非肽聚合物修饰的Fc片段的药物组合物，Fc片段的复合物和通过接头的药物和包含这样的 复杂。 由本发明的非肽肽修饰的Fc片段缺乏免疫原性和效应子功能。 由于这些性质，Fc片段以高水平维持与其结合的药物的体内活性，显着增加了药物的血清半衰期，并显着降低了诱导免疫应答的风险。